Stocks making the biggest moves premarket: Nvidia, Delta Air Lines, Eli Lilly & more

Nvidia CEO expects orders for Blackwell and Vera Rubin chips to reach $1 trillion through 2027. Delta raised first-quarter revenue growth guidance to 'high single-digit' (prior 5%-7%), and its shares jumped ~4% premarket. Oil stocks gained as crude rallied amid doubts over a U.S.-backed tanker escort plan (Exxon +1%, Occidental +1.4%, XLE +1%). Eli Lilly fell ~1.1% after HSBC downgraded to reduce, citing an inflated obesity-drug market and cautious medium-term earnings/working-capital trends.

Analysis

Nvidia’s tranche-level $T runway claim is less a single-stock thesis and more a capex re-acceleration call on the entire AI server stack: if spend steadies at ~ $150–250B/year through 2027, the immediate second-order winners are TSMC/ASML-constrained suppliers (substrates, advanced packaging, HBM vendors) and hyperscaler procurement arms that capture most incremental unit economics. That creates a multi-year demand skew where lead-time and capacity discipline (foundry/monthly allocations, substrate lead times) become bottlenecks, making timing of orders as important as headline totals — a slip in 2025-26 procurement cadence would hit multiple suppliers unevenly.

Delta’s guided revenue resilience is a near-term confirmation that consumer/business travel price elasticity remains muted, giving airlines pricing power into peak seasons; however rising crude and insurance/shipping frictions from Strait of Hormuz volatility can compress margins rapidly. Airlines with stronger balance sheets and fuel hedges will compound the benefit of higher unit revenues, while highly leveraged carriers or those with large narrowbody orders face margin squeeze if fuel continues to trend higher.

Energy moves and the HSBC take on Lilly expose asymmetric payoff profiles: oil upside from geopolitics lifts shipping, insurers, and regional E&Ps fastest, but is reversible on de-escalation or US diplomatic action within 30–90 days. For obesity/GLP-1 exposure, the market still under-weights payor and pricing risk — a broad repricing could rapidly compress multiples across incumbents, not just the poster-child names, as realized patient access and reimbursement mechanics become constraining variables over 12–24 months.

Key Decisions for Investors

• Long NVDA LEAPs (12–24 month tenor): buy NVDA Jan 2027–Jan 2028 LEAP calls (example strike area $350–$500 depending on premium). Size as core thematic (3–6% of tech book). Hedge cyclic/semiconductor risk by shorting AMD (12–18 month) or buying 1/3 sized put protection. R/R: asymmetric upside if AI capex accelerates (3x+), max downside limited to premium paid.
• Pair trade on airlines: long DAL stock or 6-month call (buy-dated 3–6 months) funded by selling 6–9 month out-of-the-money calls on a weaker carrier (e.g., UAL) to capture relative strength. Add 5–7% position-level fuel-surge tail protection (buy 2–3 month 10–15% OTM puts) to cap downside from a crude spike. R/R: capture near-term re-rating with limited tail risk.
• Short-dated energy convexity via XLE call spread (3 months): buy 1–2 month 10–15% OTM call and sell 3–4 month farther OTM call to monetize momentum while capping premium. Size small (1–3% equity) as geopolitical risk is binary; target 1.5–2.5x return on premium if Brent remains elevated, max loss equals premium.
• Directional hedge on obesity winners: buy a 6–12 month LLY put spread (e.g., buy 12-month 15–20% OTM puts, sell deeper OTM puts) sized to be 1–2% of book to express downside if payors clamp pricing. Consider pairing with short/neutral exposure to NVO to avoid broad GLP beta; R/R: limited capped loss (premium) versus 2–4x payoff if reimbursement/growth disappoints.